Navigation Links
Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Date:9/15/2008

cle also highlighted the second tumor-targeted agent in development by Epeius Biotechnologies, describing Reximmune-C as an immune stimulant, or personalized cancer vaccine, designed to be used alone or in combination with Rexin-G. Reximmune-C incorporates a powerful cytokine gene, in place of the cytocidal gene used in Rexin-G, to deliver an immune- stimulating pulse to activate a patient's own immune cells in the area of residual tumors to prevent recurrence. Remarkably, several of the prominent cancer researchers, companies, and academicians interviewed for the JNCI article focused-in principle-on the very same issues that Epeius Biotechnologies, with its definitive molecular engineering platform, has actually managed to address. The JNCI article is well worth reading.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies that are currently available for licensing and clinical development, please visit our website, http://www.epeiusbiotech.com.

For more information about Rexin-G, Reximmune-C, and on-going clinical trials in the USA and abroad, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

*(Logo Link: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
2. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
3. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
4. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
5. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
6. MacroGenics Acquires Raven Biotechnologies
7. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
8. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
9. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Weekend Weather Prompts Air Quality Advisories 54577 1Weekend Weather Prompts Air Quality Advisories 54577 2Weekend Weather Prompts Air Quality Advisories 54577 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 1The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 2The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 4The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 1Senetek PLC Reports Second Quarter 2009 Financial Results 54573 2Senetek PLC Reports Second Quarter 2009 Financial Results 54573 3Senetek PLC Reports Second Quarter 2009 Financial Results 54573 4Senetek PLC Reports Second Quarter 2009 Financial Results 54573 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 6
...itor Assay Kits are ideal for studying or screenin...ing fluorescence polarization (FP) The homogenous ... to the ligand binding domain of human progesteron...scently-tagged progesterone ligand, Fluormone PL G...
...ifically to Fc regions of many mammalian immunoglo...monly used as affinity adsorbents to purify immuno... from serum, hybridoma ascites fluids, tissue cult...e reagents are also commonly used to capture immun...
...rument engineered to match the speed of biochemica...enters worldwide. It uses 1.5 mm Roche LightCycler...-speed temperature cycling due to their thin walls...,By combining glass capillary tubes and air as th...
Freund's Incomplete Adjuvant, Modified from Calbiochem
Biology Products: